Pratley, Richard E.
Cersosimo, Eugenio
Clinical trials referenced in this document:
Documents that mention this clinical trial
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
https://doi.org/10.1185/03007995.2014.890925
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis
https://doi.org/10.1186/s12933-017-0511-0
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
https://doi.org/10.1185/03007995.2014.919907
Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data
https://doi.org/10.1186/s12933-017-0517-7
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
https://doi.org/10.1016/j.clinthera.2015.02.020
Documents that mention this clinical trial
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
https://doi.org/10.1016/j.clinthera.2015.02.020
Documents that mention this clinical trial
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Documents that mention this clinical trial
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
https://doi.org/10.1681/asn.2019121312
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
https://doi.org/10.2215/cjn.08780621
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
https://doi.org/10.1016/j.ahj.2013.05.007
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
https://doi.org/10.1185/03007995.2014.890925
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2016.04.037
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
https://doi.org/10.1185/03007995.2014.919907
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
https://doi.org/10.1016/j.amjcard.2012.08.030
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
https://doi.org/10.1016/s0140-6736(13)60683-2
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study (Results)
https://doi.org/10.2337/dc20-1889
Documents that mention this clinical trial
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
https://doi.org/10.1681/asn.2019121312
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
Are SGLT2 Inhibitors Ready for Prime Time for CKD?
https://doi.org/10.2215/cjn.07680717
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
https://doi.org/10.2215/cjn.11220720
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials
https://doi.org/10.34067/kid.0006672021
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
https://doi.org/10.1681/asn.2019010064
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
https://doi.org/10.1136/bmjopen-2017-018097
Documents that mention this clinical trial
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1355
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
https://doi.org/10.1681/asn.2018010103
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
https://doi.org/10.1136/bmjdrc-2018-000627
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc17-1096
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial (Results)
https://doi.org/10.2337/dc20-1096
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories (Results)
https://doi.org/10.2215/cjn.14901219
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Cardiovascular Effects of Noninsulin, Glucose-Lowering Agents: Need for More Outcomes Data
https://doi.org/10.1016/j.amjcard.2012.08.030
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
https://doi.org/10.1186/s12933-024-02328-6
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
https://doi.org/10.2337/dc18-1959
Documents that mention this clinical trial
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
https://doi.org/10.2337/dc18-1094
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc17-1825
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
https://doi.org/10.2337/dc17-2677
Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-0437
Liraglutide Effects in Insulin-Treated Patients in LEADER
https://doi.org/10.2337/db18-438-p
Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
https://doi.org/10.1016/j.ahj.2013.07.012
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial (Results)
https://doi.org/10.2337/dc17-1956
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc20-1622
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
https://doi.org/10.2337/dc16-2747
Liraglutide and Glycaemic Outcomes in the LEADER Trial
https://doi.org/10.1007/s13300-018-0524-z
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial (Results)
https://doi.org/10.2337/dc19-0415
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 (Results)
https://doi.org/10.2337/dci19-0067
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.2215/cjn.11881019
Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (Results)
https://doi.org/10.2337/dc19-2251
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study
https://doi.org/10.1016/j.ahj.2011.08.006
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
https://doi.org/10.2337/dc14-2868
Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
https://doi.org/10.2337/dc17-1736
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
https://doi.org/10.1016/j.clinthera.2011.06.016
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial
https://doi.org/10.2337/dc18-0109
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
https://doi.org/10.2215/cjn.05280517
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial
https://doi.org/10.1016/j.ahj.2016.01.011
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
https://doi.org/10.1016/j.ahj.2011.08.004
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
https://doi.org/10.1016/s0140-6736(14)62225-x
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
https://doi.org/10.1186/s12933-023-01802-x
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
https://doi.org/10.2337/dc20-2806
Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
https://doi.org/10.1016/j.clinthera.2014.10.009
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Pancreatic Safety of Sitagliptin in the TECOS Study
https://doi.org/10.2337/dc15-2780
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
https://doi.org/10.1016/s0140-6736(12)60691-6
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
https://doi.org/10.1186/s12933-019-0921-2
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial (Results)
https://doi.org/10.2337/dc17-1091
Diabetes, incretin hormones and cardioprotection
https://doi.org/10.1136/heartjnl-2012-303242
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype
https://doi.org/10.2337/dc17-1778
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Documents that mention this clinical trial
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.1161/circulationaha.120.048740
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
https://doi.org/10.1681/asn.2019111168
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
https://doi.org/10.1186/s12933-023-01916-2
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
https://doi.org/10.1161/circulationaha.123.065251
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria (Results)
https://doi.org/10.2215/cjn.15260920
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
https://doi.org/10.2215/cjn.10140620
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
https://doi.org/10.1007/s13300-020-00953-4
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial
https://doi.org/10.2215/cjn.08980621
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
https://doi.org/10.1161/strokeaha.120.031623
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
https://doi.org/10.1681/asn.2020050723
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
https://doi.org/10.1007/s13300-020-00968-x
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
https://doi.org/10.1136/bmjopen-2017-018097